Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Durability metrics included median duration of response 29.1 months and median PFS 30.2 months, with ongoing responses ...
Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...
The FDA has accepted a supplemental new drug application and granted priority review to elinzanetant (Lynkuet) for moderate ...
Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.
Jeffrey V. Matous, MD, discusses moving fixed-duration T-cell–redirecting therapy into frontline multiple myeloma treatment ...
C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
FDA labeling now reports a 49.7-month median DOR in TKI-naive advanced ROS1+ NSCLC from TRUST-I, based on 51-month median ...
The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...
The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...
David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results